anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This invention provides polynucleotides coding for mammalian polypeptides that are multiple function regulatory proteins (MFRP) and fragments of the polynucleotides. These polynucleotides are isolated from the native environment or they are recombinantly produced. Also provided by this invention are purified, naturally occurring MFRP and recombinantly produced MFRP and polypeptide fragments of these proteins. Antibodies, both polyclonal and monoclonal, are further provided herein as well as the hybridoma cell lines which produce the monoclonal antibodies. These antibodies are characterized by specifically binding the proteins and polypeptide fragments of this invention. Compositions containing an excipient and any of the polynucleotides, proteins, polypeptides and antibodies of this invention are further provided herein. Finally, diagnostic and therapeutic uses of these compositions also are provided by this invention.
Participants will receive 100-mg anacetrapib, orally, once-daily for 24 weeks. Participants will continue on once-daily 100-mg anacetrapib during 28 week open-label extension.
In this active Group will be enrolled only infant who are bottle-fed. This Group will take the active product containing 5 drops of active product (108 viable cells/strain) of Bifidobacterium breve BR03 and Bifidobacterium breve B632.
OBJECTIVE: To assess the effectiveness and safety of a rigorous short-term supine position in preventing inadvertent retinal displacement after pars plana vitrectomy (PPV) with gas tamponade for rhegmatogenous retinal detachment (RRD).
METHODS: We conducted a retrospective observational analysis of a case series at two ophthalmological surgical centers. We included eyes diagnosed with macula-off RRD that maintained a strict face-up position for three hours immediately after PPV with intraoperative perfluorocarbon liquid (PFCL) and 20% sulfur hexafluoride (SF6) tamponade. Fundus autofluorescence (FAF) imaging was performed at one month post-operatively to identify unintentional retinal displacement through the detection of retinal vessel prints (RVPs) on FAF imaging using an ultrawide-field (UWF) imaging system.
RESULTS: A total of 29 eyes with macula-off RRD were included in the study. The average age of the participants was 59.62 years. RRD involved one quadrant in two eyes, two quadrants in fourteen eyes, three quadrants in seven eyes, and four quadrants in six eyes. UWF-FAF imaging at one month follow-up after complete reattachment of the retina revealed RVPs in seven out of the 29 eyes (24.13%), with a mean displacement of 0.22 mm. In every case the displacement occurred downward.
CONCLUSION: Our results suggest that adhering to a strict face-up position for three hours after PPV with PFCL and gas tamponade for macula-off RRD may lead to a low frequency and severity of inadvertent post-operative retinal displacement.
A self-development method that is configured to be facilitated by a software application wherein the present invention the user is taught about a plurality of self-knowledge tools and guided therethough. The present invention further includes providing of a graphical interface environment during utilization thereof. The graphical interface environment includes a plurality of three-dimensional avatars that include but are not limited to a personal three-dimensional avatar and a wisdom guide avatar. The software application of the present invention facilitates data collection throughout utilization thereof wherein the data collection is compiled for analysis in a personal database. Data input is collected by either voice input or text input. The personal database is populated utilizing the tools within the software and subsequent activities and/or actions are required to be performed by the user in order to drive improvement in the category.
The present invention relates to a method for providing medical guide information through an electronic chart, an apparatus therefor, and a recording medium recording the same. The present invention provides the medical guide information capable of establishing a treatment plan, and supporting a treatment to a user through the electronic chart. Therefore, a time required for searching information when establishing the treatment plan through the electronic chart can be effectively reduced, and the overall medical quality can be improved. The method for providing the medical guide information through the electronic chart comprises the following steps. The medical guide information providing apparatus receives treatment plan information in the electronic chart through a user interface. The medical guide information providing apparatus extracts at least one key word by analyzing the received treatment plan information. The medical guide information providing apparatus searches guide information which can establish a treatment plan and guide a treatment as information related to the treatment plan information based on the key word. The medical guide information providing apparatus verifies a position of an empty area where the information is not displayed on the electronic chart, and the size of the empty area. The medical guide information providing apparatus determines whether to display the guide information, and determines a display format based on the importance of the guide information according to the verified position and the size of the empty area, and a preset standard. The medical guide information providing apparatus determines a display position to display the guide information of the empty area to group and to provide the guide information according to a category categorized based on a subject and contents of the guide information. And the medical guide information providing apparatus displays the guide information on the electronic chart in response to the determined display format and the display position.
Lavage group of high-concentration sugar solution (HCSS): disinfected the Skin outside wound with conventional PVP. HCSS refers to supersaturated sugar solution made of 50% high-concentration glucose and white sugar. Prior to wound irrigation, dry cotton balls are used to wipe the wound and internal lacuna, to clean some necrotic tissues out of the wound. HCSS is applied on the wound once a day, and whether the lavaging is stopped based on the amount of exudation from the wound.
Patients who routinely have punch skin biopsy for diagnostic purposes and who were both clinically and histopathologically diagnosed with mycosis fungoides will be included. Patients who only have mycosis fungoides patch lesion on their body, over the age of 18, and who have not received topical treatment for the last 2 weeks or systemic therapy for 4 weeks will be included. Demographic, clinical, videodermoscopy, capillaroscopy (lesional) and histopathological data will be recorded.
Patches for application to the skin comprise a matrix that is adhesive in the dry state and contains an active material. Adhering to one face of the matrix is a support, and the other face is applied to the skin. The support is able to hold a liquid that dissolves, at least partially, the active material held in the matrix, the matrix being permeable to this liquid.  The matrix (2) is a hydrophobic polymer coated on one face by a removable protective coating (4), the other face being attached to a porous support (6). The active material is preferably present in the matrix in particulate form, the liquid that dissolves it is aqueous or alcoholic. The active material is preferably dermatologically active, such as an emollient, hydrating agent, cicatrizing agent, regenerating agent, anti-wrinkle agent, toning agent, insensitizer, solar protector, soothing agent, self-tanning agent, lightening agent, anti-freckle agent, fat reducing agent, or their mixtures. The support may be made of a super-absorbent cross-linked polyacrylate, polyvinyl alcohol, a carboxyvinyl polymer, a cellulose semi-synthetic derivative, starches, bio-gums, biosaccharides, scleroglucans, casein, phytocolloids such as alginates, gelatin, cotton fibers, silicas, and their mixtures. The matrix is of one or more polymers, preferably hydrophobic, and may contain micro-perforations and may be deposited on the support in the form of a grille. Impregnation of the support with the liquid may take place before the patch is packaged, or at the time it is used.
Person-centered care is a system of care delivery that supports effective patient-clinician communication and empowers patients to partner with their clinical providers to develop goal-concordant treatment plans. Models of person-centered care often involve the implementation of patient-reported outcomes (PROs) to measure patients' symptoms and quality of life as they navigate complex chronic health conditions. Models of person-centered care have been particularly effective in improving the quality of care delivery for older adults as well as younger adults with aging-associated conditions such as physical function decline. Though PROs have been developed and validated in kidney disease, they are not routinely implemented in clinical practice. Most individuals with kidney disease are 65 and older, but many younger individuals with kidney disease also experience aging-associated conditions earlier than in the general population. Thus, PROs represent an important tool for achieving person-centered care in groups with kidney disease who are the most vulnerable to adverse health outcomes and excess health care utilization. In this article, we aim to move toward more routine implementation of PROs in kidney care for aging adults. To identify the most clinically relevant PROs for this group and understand the ideal mode and context in which to implement PROs, we will (1) provide an evidence-based summary of PROs with the greatest prognostic significance in the general population and in kidney disease, including those specific to older adults; (2) describe barriers to the implementation of PROs in kidney care with a special focus on the needs of older adults and younger adults with aging-associated conditions; and (3) conclude with our evidence-based recommendations for the content, time, and context in which PROs should be implemented to achieve person-centered kidney care for aging adults.
PRIMARY OBJECTIVES: I. To determine the safety, tolerability and recommended Phase II dose of temsirolimus in combination with vorinostat in patients with metastatic, hormone refractory, chemoresistant prostate cancer. II. To obtain preliminary evidence of response in prostate cancer patients treated with temsirolimus and vorinostat. SECONDARY OBJECTIVES: I. To determine the partial and complete objective response rates in metastatic hormone-refractory, chemo-resistant prostate cancer patients with measurable disease treated with temsirolimus and vorinostat. II. To determine the progression free survival and overall survival in patients with metastatic hormone refractory, chemo-resistant prostate cancer. III. To determine the PSA response, the duration of PSA response, time to PSA progression, PSA doubling time and PSA slope in metastatic hormone refractory, chemo-resistant prostate cancer patients treated with temsirolimus and vorinostat. IV. To assess changes in expression levels of bone remodeling markers (N telopeptides and bone alkaline phosphatase) and angiogenesis-related gene and protein expression (VEGF/HIF1-alpha) in blood and circulating tumor cells, and when available, in tissue, and correlate them with cancer and treatment related outcomes. V. To assess the changes in tumor metabolism with FDG/IIC-Choline PET/CT scan. OUTLINE: Patients receive oral vorinostat once daily on days 1-14 and temsirolimus IV on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed at 30 days and then every 3 months thereafter.
Metallic iron powder for medical use is rendered more readily soluble in the gastric juices by bringing the particles into permanent contact with small proportions of platinum ruthenium, osmium, iridium or rhodium by depositing such metal by reduction on the metallic iron powder, or by reducing a compound of the metal simultaneously with a compound of iron.  The specified metals have a lower hydrogen over-voltage than that of iron so that polarization by the hydrogen evolved on solution is reduced, and the iron dissolves more quickly and completely.  The second metal is used in proportions of 0,1 to 1 per cent and is insufficient to form a complete coating on the iron particles. The powder may be made up in the form of tablets by coating with digestible material such as chocolate and malt, or doses of the powder may be provided with an air- and water-tight coating of an alcoholic solution of vegetable resins.  According to examples: (1) reduced iron powder is added to an aqueous solution of platinic chloride, through which carbonic acid is passed, so that the platinium is deposited on the iron; (2) an acid solution of ferrous sulphate is mixed with a solution of platinum chloride, caustic soda is added, and the precipitate obtained is washed, dried, pulverized and reduced by heating in a current of hydrogen. Specification 386,499, [Group II], is referred to.ALSO:Metallic iron powder for medical use is rendered more readily soluble in the gastric juices by bringing the particles into permanent contact with small proportions of platinum, ruthenium, osmium, iridium or rhodium by depositing such metal by reduction on the metallic iron powder, or by reducing a compound of the metal simultaneously with a compound of iron.  The specified metals have a lower hydrogen over-voltage than that of iron so that polarization by the hydrogen evolved on solution is reduced, and the iron dissolves more quickly and completely.  The second metal is used in proportions of 0,1 to 1 per cent and is insufficient to form a complete coating on the iron particles. According to examples: (1) reduced iron powder is added to an aqueous solution of platinic chloride, through which carbonic acid is passed, so that the platinum is deposited on the iron; (2) an acid solution of ferrous sulphate is mixed with a solution of platinum chloride, caustic soda is added, and the precipitate obtained is washed, dried, pulverized and reduced to the metallic state by heating in a current of hydrogen. Specification 386,499 is referred to.
1. Technical Result Improvement of medicinal properties of pharmaceutical composition.          2. Essence A composition comprises levosimendan in therapeutically effective amount and a component regulating release of medicament and capable of releasing levosimendan in a controlled fashion during the long period of time; as the component the pharmaceutical composition preferably contains hydrophilic gel-forming polymer or vegetable oil or fat acid ether.          3. Field of Application Medicine.                 Tables 5
BACKGROUND: Observational study investigated the association between pernicious anemia (PA) and cancers. However, with the exception of gastric cancer, the results are mostly contradictory. The purpose of this study was to investigate the potential causal relationship between PA and cancers through bidirectional two-sample Mendelian randomized (MR) analysis.
METHODS: The European sample FinnGen project provided the genetic summary data for PA and 20 site-specific cancers. This bidirectional two-sample MR design mainly used the inverse variance weighting (IVW) method to evaluate the causal relationship between PA and cancer risk. Benjamini-Hochberg correction was performed to reduce the bias caused by multiple tests.
RESULTS: Our study shows that there was a causal relationship between PA and gastric cancer, prostate cancer, testicular cancer and malignant melanoma of skin, and there was a reverse causal relationship between prostate cancer or gastric cancer and PA (P < 0.05). After Benjamini-Hochberg correction test, there was still a causal correlation between PA and gastric or prostate cancer (P' < 0.05), while there was only an implied causal association between PA and testicular cancer and malignant melanoma of skin (P'> 0.05). There was still a reverse causal relationship between gastric cancer and PA (P'< 0.05), while prostate cancer shows an implied reverse causal relationship(P'> 0.05). In addition, MR-Egger and MR-PRESSO tests showed no significant horizontal pleiotropy.
CONCLUSIONS: PA may be genetically associated with testicular cancer, prostate cancer, gastric cancer, and malignant melanoma of skin.
The current invention relates to an effector moiety capable of inducing an intracellular effect when present inside a mammalian cell, the effector moiety comprising a payload conjugated with at least one saponin. The invention also relates to an antibody-drug conjugate comprising the effector moiety according to the invention, or a ligand-drug conjugate comprising the effector moiety of the invention, the effector moiety comprising covalently coupled saponin. The invention also relates to a therapeutic combination comprising: (a) the effector moiety of the invention, comprising at least one saponin, and optionally a pharmaceutically acceptable excipient; and (b) an antibody-drug conjugate or a ligand-drug conjugate, and optionally a pharmaceutically acceptable excipient. Further, the invention relates to a pharmaceutical composition comprising the effector moiety of the invention or the antibody-drug conjugate of the invention or the ligand-drug conjugate of the invention, comprising at least one saponin covalently linked to the effector molecule, and optionally a pharmaceutically acceptable excipient. The invention also relates to the effector moiety of the invention or the antibody-drug conjugate of the invention or the therapeutic combination of the invention or the ligand-drug conjugate of the invention or the pharmaceutical composition of the invention, for use as a medicament. Finally, the invention also relates to the effector moiety of the invention or the antibody-drug conjugate of the invention or the therapeutic combination of the invention or the ligand-drug conjugate of the invention or the pharmaceutical composition of the invention, for use in the treatment or prevention of a cancer or an autoimmune disease.
Breast cancer (BC) is the most common malignancy affecting Western women today. It is estimated that as many as 10% of BC cases can be attributed to germline variants. However, the genetic basis of the majority of familial BC cases has yet to be identified. Discovering predisposing genes contributing to familial BC is challenging due to their presumed rarity, low penetrance, and complex biological mechanisms. Here, we focused on an analysis of rare missense variants in a cohort of 12 families of Middle Eastern origins characterized by a high incidence of BC cases. We devised a novel, high-throughput, variant analysis pipeline adapted for family studies, which aims to analyze variants at the protein level by employing state-of-the-art machine learning models and three-dimensional protein structural analysis. Using our pipeline, we analyzed 1218 rare missense variants that are shared between affected family members and classified 80 genes as candidate pathogenic. Among these genes, we found significant functional enrichment in peroxisomal and mitochondrial biological pathways which segregated across seven families in the study and covered diverse ethnic groups. We present multiple evidence that peroxisomal and mitochondrial pathways play an important, yet underappreciated, role in both germline BC predisposition and BC survival.
Deep functional and structural neuroimaging of a series of Gerstmann's syndrome patients required high accuracy, and our results avoided false overlaps of heterogeneous brain lesions by handling each case of our study subjects separately as an individual case regarding functional and neuroimaging tests. Six patients with Gerstmann tetrad (one with dominant acalculia, one with dominant left and right disorientation, two with writing disabilities and two with finger agnosia) and 6 control subjects with close ages were recruited in the current study. In the main phase, we assessed brain activation in response to experimental and interventional settings using neuroimaging techniques (FMRI-Functional Magnetic Resonance Imagingwhere twelve pictures were taken on a Dell inspiration 3T all-body scanner with sequences of echo pictures, 80o angled, TE 35 ms) of the subject's brain to declare lesions existence and locations that might result in one of the four cognitive impairment domains of Gerstman's syndrome tetrad. We assessed statistically significant differences of patient images vs. control images as well as the images of patients presenting specific symptomatic cognitive dysfunction domain vs. the images of patients presenting the three other domains. Neuroimages were analyzed using multiple databases such as T1 weighted and free sequence types. Gerstmann's syndrome is mainly connected to injury in the dominant parietal lobe, so images comparisons and analysis were only restricted to the left parietal lobe region. P values <0.05were only considered as statistically significant difference in comparisons of functional tests time and accuracy of patients vs. in addition to comparisons of brain images parameters of patient group vs. control group and specific symptomatic domain patients vs. other symptomatic domains patients. Regarding functional testing, Patients group took significantly higher time compared to control group. Regarding brain images parameters, patients in each domain showed significantly different lesions compared to other domains. Moreover, control subjects showed no lesions in the left parietal lobe compared to significant lesions in the patient groups. These results oppose the theory of Gerstmann that a common brain structural injury may result in the combination of all of the four symptomatic dysfunction domains. This may be due to the fact that Gerstmann examined incomplete cases which represent a considerable criticism to his scientific basis. Moreover, he excluded patients with speech difficulties and apraxia.
The following trial evaluates the effect of Tremor Stabilization Algorithms on involuntary hand tremors suffered by Parkinson's patients. These algorithms will be implemented in Virtual Reality (VR). Approximately 300 study subjects are to be randomized to experimental (VR plus algorithms, i.e., intervention) and active comparator (VR only, i.e., control) study arms. Study subjects will perform a postural tremor test (PTT) to elicit postural parkinsonian tremors. Our primary outcome is whether the intervention modifies tremor severity. Secondary outcomes include determining whether tremor severity is reduced long-term. These measurements will occur 5 minutes to 30 days post-intervention and will not involve VR. Other secondary outcomes include determining age-of-onset impact on tremor severity, and online self-report surveys for functionality in life in general and in the context of Parkinson's disease. Subjects will perform tremor-recordings on-site. Self-reports will be remote.